Used primarily as a key intermediate in the development of angiotensin II receptor antagonists for the treatment of hypertension. Its structural properties contribute to high selectivity and binding affinity to the AT1 receptor in the final drug, promoting effective blood pressure control. The compound is designed to improve metabolic stability and oral bioavailability of the resulting medications, making them suitable for once-daily dosing in antihypertensive treatments. It also contributes to reducing the risk of cardiovascular events in patients with chronic high blood pressure. Its methylsulfonyl-containing side chain enhances solubility and pharmacokinetic profile of the drug, supporting formulation in tablet dosage forms.